TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas
M Melo, AG da Rocha, J Vinagre… - The Journal of …, 2014 - academic.oup.com
The Journal of Clinical Endocrinology & Metabolism, 2014•academic.oup.com
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-
derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.
Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid
lesions and to investigate the prognostic significance of such mutations in a large cohort of
patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective
observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A …
derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.
Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid
lesions and to investigate the prognostic significance of such mutations in a large cohort of
patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective
observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A …
Context
Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.
Objectives
We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs).
Design
This was a retrospective observational study.
Setting and Patients
We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years.
Main Outcome Measures
Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality.
Results
TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs.
Conclusions
TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC.
Oxford University Press